Drug discovery, re-engineered for cancer.
BrainOmega is a Generative AI-native discovery platform turning cancer biology into clinical-ready candidates — faster, with full audit and governance built in.
10× faster cycles. Higher hit rate.
Our Product compresses in-silico discovery from years to weeks — and scores every candidate with calibrated AI, so only the strongest and most promising candidates reach your lab.
Less time wasted. Fewer dead ends. More wins.
Discovery cycles, compressed.
BrainOmega lets oncology teams test more biology in less time — with predictions you can defend in front of regulators, partners and your scientific board.
Built for teams that have to defend their decisions.
Six things every partner asks about — and we built the platform around the answers.
Audit-ready by design
Every prediction carries a content hash, model version and timestamp. Replay any decision, any time.
Calibrated confidence
Models output uncertainty bands, not just point estimates — so chemists know when to trust them.
Cancer-specialised
No generic chem-tools. Every head is tuned for the four anchor drivers and validated against real bioactivity.
Whole-system simulation
Chemistry, biology, PK and resistance in one loop — not five disconnected vendors.
EU-hosted, GDPR-native
Barcelona-based infrastructure. Data sovereignty without paperwork gymnastics.
Human-in-the-loop
BrainOmega augments the chemist — not the other way around. Every model output is a defensible suggestion, not a black box.
Built for the way your team actually works.
BrainOmega plugs into pharma, biotech, academic and investor workflows. We do not sell a black box — we run real programs with you.
Co-development
Run anchor-driver programs end-to-end on the platform with shared milestones and IP arrangements.
- Dedicated program team
- On-prem / VPC deployment options
- Co-authored model cards & audit packs
- Milestone-based commercials
Embedded discovery
Lean teams use BrainOmega as their discovery backbone — generation, scoring and governance from day one.
- Workspace per program
- API + UI access
- Investor-ready audit trail
- Annual + per-program pricing
Research access
Joint publications and shared benchmarks — academic groups publishing in oncology drug discovery.
- Free academic seats
- Joint publications & code release
- Open benchmark contributions
- PI-led grant collaboration
Pipeline & DD
Briefings for VCs and corporate venture teams — clear-eyed views on platform capability, programs and commercials.
- Quarterly investor briefing
- Live platform walkthrough
- Independent DD access
- Reference portfolio comps
Become a BrainOmega partner.
We onboard one new partner per quarter. Tell us what you are working on — we will match the engagement model.
Ship faster. Decide better.
Tell us about your program — pharma, biotech, academic group or VC due-diligence — and we will get back within one business day.
BrainOmega is in private beta with a small number of pharma and biotech partners across the EU. We work hands-on with your team — discovery, computational chemistry and program leads alike.
- Emailcontact@brainomega.ai
-
HQCalle de Pau Gargallo, 30
entrada Pascual i Vila
Barcelona, Catalonia 08028, ES